Utilizing Nobel Prize
winning science

The 2021 Nobel Prize in Physiology or Medicine was awarded in part to Dr. David Julius – for identifying TRPV1 as a molecular heat sensor.

Since its original discovery, further research has demonstrated that the TRPV1 receptor plays a role in neuroinflammatory conditions.  

Next Generation Immunomodulation

AazeinTx’s NEO6860 immunomodulator is a next generation molecule that has a robust safety profile, and has already been tested in over 118 patients. This new and improved molecule solved many of the problems associated with the first generation TRPV1 antagonists and demonstrated safe in to use in humans.

Clinical Validation

NEO6860 has already been tested in 118 humans. This next generation immunomodulatory solved many of the problems associated with the first generation TRPV1 antagonists.

Preserves protons & heat Sensitivity

First generation TRPV1 antagonists act on the receptor's heat sensing, causing patients to be at risk for hypothermia and other complications. NEO6860 does not act on TRPV1's heat sensing capabilities.

Preserves Physiological Functions

NEO6860 reserves primary physiological functions in TRPV1 which are important for heat and acid sensing. NEO6860 also prevents pathological modulation by capsaicin/inflammatory mediators.

Focused on Neuroinflammatory Diseases

The TRPV1 receptor plays a parallel role in inflammation & local inflammation that activates the nervous system. This in turn exacerbates inflammation, leading to organ-specific dysfunction. 

Asthma causes 400,000 deaths per year, with 1/3 occurring in hospital. 

AazeinTx has already demonstrated strong preclinical potential for NEO6860 in abating acute asthma attacks, and is ready to move into phase 2 clinical trials. 

Febrile seizures (FS) are the most common seizure disorder in children 9 months – 5 years.

1 in every 25 children will experience at least one FS during their childhood. There is a significant unmet need with no safe and widely used treatment currently available. 

Data suggests a connection between febrile seizures and the TRPV1 receptor. Animal models have demonstrated that a safe and effective immunomodulator could help abate febrile seizures. 

Paclitaxel is a second line therapy for solid tumors (breast, prostate, lung, testicular). Paclitaxel is 86-100% effective but a common side effect is painful acute peripheral sensory neuropathy (burning sensations, mechanical allodynia, numbness, tingling)

Data suggests a connection between peripheral sensory neuropathic pain caused by chemotherapy and the TRPV1 receptor. Efficacy has been demonstrated in animal models. 

Studies show as many as 16% of women in the U.S. will experience Vulvodynia at some point in their lives. It is characterized by a burning, itching, or otherwise chronic painful sensation in the vulva. 

Data suggests Vulvodynia can increase TRPV1 expression. 

Asthma and COPD are related diseases and may form a continuum; potential treatments could coincide. For example, asthma and COPD involve airway inflammation, excess production of mucus and airway smooth-muscle thickening. 

Data has shown that repeated systemic doses of a TRPV1 modulator reverses multiple measures of chronic lung inflammation. 

Reach out
to learn more